Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms.
| dc.rights.license | open | en_US |
| hal.structure.identifier | Nutrition et Neurobiologie intégrée [NutriNeuro] | |
| dc.contributor.author | LASSELIN, Julie | |
| hal.structure.identifier | Nutrition et Neurobiologie intégrée [NutriNeuro] | |
| dc.contributor.author | CAPURON, Lucile
IDREF: 167018736 | |
| dc.date.accessioned | 2022-03-16T10:08:25Z | |
| dc.date.available | 2022-03-16T10:08:25Z | |
| dc.date.issued | 2014-01-01 | |
| dc.identifier.issn | 1423-0216 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/136485 | |
| dc.description.abstractEn | The ability of cytokines to influence cerebral functions and to induce the development of behavioral alterations is well established in conditions of acute or chronic high-grade activation of the innate immune system. Recent evidence suggests that the release of these immune mediators during chronic low-grade endogenous inflammatory processes may also contribute to the development of behavioral alterations. Metabolic disorders, including obesity, type 2 diabetes and the metabolic syndrome, represent examples of those conditions which are both characterized by a chronic low-grade inflammatory state and an increased prevalence of behavioral disorders. In metabolic disorders, the increased production of acute-phase proteins and cytokines (e.g. C-reactive protein, interleukin-6 and tumor necrosis factor-α), but at relatively low levels, may promote and contribute to the development of behavioral symptoms, including depressive symptoms, cognitive impairment, fatigue, sleep problems and pain. This hypothesis is supported by a growing literature referring both to experimental and clinical findings that will be reviewed here. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Animals | |
| dc.subject.en | Behavioral Symptoms | |
| dc.subject.en | Humans | |
| dc.subject.en | Metabolic Diseases | |
| dc.title.en | Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms. | |
| dc.title.alternative | Neuroimmunomodulation | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1159/000356535 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
| dc.identifier.pubmed | 24557041 | en_US |
| bordeaux.journal | Neuroimmunomodulation | en_US |
| bordeaux.page | 95-101 | en_US |
| bordeaux.volume | 21 | en_US |
| bordeaux.hal.laboratories | NutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286 | en_US |
| bordeaux.issue | 2-3 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INRAE | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.export | false | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neuroimmunomodulation&rft.date=2014-01-01&rft.volume=21&rft.issue=2-3&rft.spage=95-101&rft.epage=95-101&rft.eissn=1423-0216&rft.issn=1423-0216&rft.au=LASSELIN,%20Julie&CAPURON,%20Lucile&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||